A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension

This publication has 43 references indexed in Scilit:

• Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy
  British Journal of Dermatology, 2008
• Nonmelanoma Skin Cancer and Risk for Subsequent Malignancy
  JNCI: Journal of the National Cancer Institute, 2008
• Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis
  Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2006
• Genetics and risk factors for basal cell carcinoma
  British Journal of Dermatology, 2006
• Hypersensibilité à la dacarbazine chez les malades traités pour mélanome métastatique
  Annales de Dermatologie et de Vénéréologie, 2006
• Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin
  British Journal of Dermatology, 2005
• Multiple Emulsion Stability: Pressure Balance and Interfacial Film Strength
  Journal of Colloid and Interface Science, 2002
• Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
  Annals of Oncology, 2001
• Gastrinoma with multiple liver metastases: Effectiveness of dacarbazine (DTIC) therapy
  Journal of Hepato-Biliary-Pancreatic Surgery, 1998
• In vivo metabolism and reaction with dna of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC)
  Biochemical Pharmacology, 1986